Abstracts Archive - Page 285 of 2607 - ACR Meeting Abstracts

Abstract Number: 0644 • ACR Convergence 2024
Scoping Literature Review to Identify Candidate Domains for the SLE OMERACT Core Outcome Set
Wils Nielsen¹, Fadi Kharouf², Carolina Munoz-Grajales³, Aarabi Thayaparan⁴, Melanie Anderson⁵, Lee Simon⁶, Maya Desai⁷, Ioannis Parodis⁸, Alfred Kim⁹, Yvonne Enman¹⁰, Kathleen Bingham¹¹, Dennisse Bonilla¹¹, Julian Thumboo¹², Marta Mosca¹³, Martin Aringer¹⁴, Eric Morand¹⁵, Ian Bruce¹⁶, Vibeke Strand¹⁷ and Zahi Touma⁴, ¹University of Toronto, Markham, ON, Canada, ²University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ³UHN/TWH, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵The Institute for Education Research, Library and Information Services, University Health Network, Toronto, ON, Canada, ⁶SDG LLC, West Newton, MA, ⁷Ontario College of Art and Design University, Toronto, ON, Canada, ⁸Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, ⁹Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO, ¹⁰Karolinska Institutet, Stockholm, Sweden, ¹¹University Health Network, Toronto, ON, Canada, ¹²Singapore General Hospital, Singapore, Singapore, ¹³University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy, ¹⁴University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, ¹⁵School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, ¹⁶Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, ¹⁷Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: The Outcome Measures in Rheumatology (OMERACT) Systemic Lupus Erythematosus (SLE) Working Group was re-established in 2018 to update the SLE Core Outcome Set (COS)…
Abstract Number: 0569 • ACR Convergence 2024
The Longitudinal Association Between Disease Activity, Function and Health-Related Quality of Life in Axial Spondyloarthritis: Results from the DESIR Cohort
Augusta Ortolan¹, Desiree van der Heijde², Laure Gossec³ and Sofia Ramiro⁴, ¹Policlinico Universitario Agostino Gemelli IRCSS, Rome, Lazio, Italy, ²Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ³Sorbonne Université, Paris, France, ⁴Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Health-related quality of life (HRQoL) in axSpA is considered an overarching outcome, with other disease outcomes contributing to it [1]. To validate a previously…
Abstract Number: 0633 • ACR Convergence 2024
Novel LINE-1 Reverse Transcriptase Inhibitors Can Suppress Type I Interferon Responses and Are Promising Therapeutics for Lupus
Wenyan Miao¹, Digna de Bruin², Cedric Arisdakessian¹, Jannik Rousel², Jared Steranka¹, Matthijs Moerland², Eric Jacobson¹, Mehrnaz Gharaee-Kermani³, Liyang Diao¹, Craig Dobry³, Nafeeza Hafeez¹, Brian Desrosiers¹, J. Michelle Kahlenberg³, Heike Keilhack¹, Robert Rissmann², Keith M Wilcoxen¹ and Tessa Niemeyer-van der Kolk², ¹Rome Therapeutics, Boston, MA, ²Centre for Human Drug Research, Leiden, Netherlands, ³University of Michigan, Ann Arbor, MI
Background/Purpose: Long Interspersed Element-1 (LINE-1) retrotransposon encodes for two proteins, ORF1p and ORF2p. ORF1p is a chaperone protein while ORF2p contains reverse transcriptase (RT) and…
Abstract Number: 0635 • ACR Convergence 2024
Medical Record Natural Language Processing and Patient Biometric and Self-Reported Measures Inform an Artificial Intelligence Augmented Remote Care Management Strategy for Lupus Patients
Gerald Lushington¹, Bruce Wang², Mohan Purushothaman³, Melissa Munroe⁴, Vijay R. Nadipelli⁵, Bernard Rubin², Jessica Crawley², Beth Valashinas⁶, Reshma Khan⁷, Anil Warrier⁸, Joseph Huffstutter⁹, Jennifer Murphy¹⁰, Lizeth Santamaria², Sneha Nair², Georg Armstrong², Sandeep Nair², Daniele DeFreese³, Adrian Holloway³, Arif Sorathia², Brett Adelman², Fabricio Pautasso² and Eldon Jupe³, ¹Progentec Diagnostics, Inc, Oklahoma City, OK, ²Progentec Diagnostics, Inc., Oklahoma City, OK, ³Progentec Diagnostics, Inc., Oklahoma City, ⁴Oklahoma Medical Research Foundation; Progentec Diagnostics, Inc., Oklahoma City, OK, ⁵GSK, Medical Evidence Generation, Philadelphia, PA, ⁶Physicians Alliance of Connecticut, Milford, CT, ⁷Palm Beach Rheumatology and Wellness Center, Jupiter, FL, ⁸Millennium Rheumatology, Conroe, TX, ⁹Arthritis Associates PLLC, Signal Mountain, TN, ¹⁰Articularis Healthcare, Summerville, SC
Background/Purpose: Systemic lupus erythematosus (SLE) is one of several rheumatologic disorders that presents frequent healthcare challenges, particularly for socioeconomic and geographically disadvantaged patients. Due to…
Abstract Number: 0537 • ACR Convergence 2024
Evaluating the Usage of Janus Kinase Inhibitors in Rheumatology and Its Impact on Cardiovascular Risk
Knkush Hakobyan¹, Talar Acob², Mesrop Aleksanyan³, Tigran Kakhktsyan³, Omar Jumaah³ and Sajina Prabhakaran⁴, ¹Capital Health medical center, Princeton, NJ, ²College of medicine-university of Baghdad, Plainsboro Township, NJ, ³Capital Health Medical Center, Trenton, ⁴Capital health Rheumatology specialists, Newtown, PA
Background/Purpose: Janus kinase (JAK) inhibitors have been widely used in treatingrheumatological conditions like rheumatoid arthritis and psoriatic arthritis. Despite theirefficacy, there are concerns regarding major…
Abstract Number: 0659 • ACR Convergence 2024
Obinutuzumab Benefits Patients with Active Lupus Nephritis Irrespective of Baseline Proteinuria Severity: A Post Hoc Analysis of a Phase II Trial
Richard Furie¹, Jorge A. Ross Terres², Elsa Martins³, Imran Hassan⁴, Thomas Schindler³, Jay Garg⁵, William F. Pendergraft III⁶, Ana Malvar⁷ and Brad Rovin⁸, ¹Northwell Health, Manhasset, NY, ²Genentech, Inc,, San Francisco, ³F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁴Hoffmann-La Roche Ltd, Mississauga, Canada, ⁵Genentech, Inc., South San Francisco, CA, ⁶Genentech, Inc., Chapel Hill, NC, ⁷Organización Médica de Investigación, Buenos Aires, Argentina, ⁸The Ohio State University, Columbus, OH
Background/Purpose: Lupus nephritis (LN) is the most common severe organ-threatening manifestation of systemic lupus erythematosus (SLE). The randomized, placebo-controlled, Phase II NOBILITY trial (NCT02550652) demonstrated…
Abstract Number: 0582 • ACR Convergence 2024
Achievement of Minimal and Very Low Disease Activity Among Patients with Psoriatic Arthritis Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/SpA Registry
Alexis Ogdie¹, Chao Song², Nicole Middaugh³, Maya Marchese³, Melissa Eliot³, Robert Low² and Philip Mease⁴, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²UCB Pharma, Smyrna, GA, ³CorEvitas, LLC, Waltham, MA, ⁴Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Minimal disease activity (MDA) is associated with clinically meaningful improvements in disease activity and patient (pt)-reported outcomes among pts with PsA.1 However, it is…
Abstract Number: 0551 • ACR Convergence 2024
Evaluation of Instruments Assessing Peripheral Arthritis in Spondyloarthritis: An Analysis of the ASAS-perSpA Study
Dafne Capelusnik¹, Anna Molto², Clementina López Medina³, Desiree van der Heijde⁴, Robert Landewé⁵, Maxime Dougados⁶, Joachim Sieper⁷ and Sofia Ramiro⁸, ¹Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ²Groupe Hospitalier Cochin, AP-HP, Paris, France, ³Reina Sofia University Hospital, Cordoba, Spain, ⁴Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ⁵Amsterdam University Medical Center, Meerssen, Netherlands, ⁶Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, ⁷Charité University Medicine Berlin, Berlin, Germany, ⁸Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: The optimal instrument to assess peripheral arthritis and related disease activity in SpA has not yet been identified. In the recent update of the…
Abstract Number: 0331 • ACR Convergence 2024
Cardiac Manifestations in Patients with Anti-Synthetase Syndrome: Analysis from the “Classification Criteria for Anti-synthetase Syndrome (CLASS)” Project Database
Sangmee Bae¹, Gianluca sambataro², iazsmin Ventura³, Francisca Bozan⁴, Eduardo Dourado⁵, Sara Faghihi-Kashani⁶, Aravinthan Loganathan⁷, Daphne Rivero Gallegos⁸, Akira Yoshida⁹, Giovanni Zanframundo¹⁰, Francesco Bonella¹¹, Tamera J Corte¹², Tracy J Doyle¹³, david fiorentino¹⁴, Miguel Angel Gonzalez-Gay¹⁵, marie Hudson¹⁶, Masataka Kuwana¹⁷, Andrew Mammen¹⁸, Neil McHugh¹⁹, Frederick Miller²⁰, Carlomaurizio Montecucco²¹, Antonella Notarnicola²², Chester Oddis²³, Jorge Rojas-Serrano²⁴, Jens Schmidt²⁵, Carlo A. Scire²⁶, Albert Gil-Vila²⁷, Victoria Werth²⁸, Lorenzo Cavagna²⁹ and Rohit Aggarwal³⁰, ¹UCLA, Los Angeles, CA, ²University of Catania, Catania, Italy, ³Section of Rheumatology, University of Chicago, Chicago, IL, ⁴Hospital Clinico Universidad de Chile, Santiago, Chile, ⁵Unidade Local de Saúde da Região de Aveiro, Aveiro, Portugal, ⁶Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, San Francisco, CA, ⁷Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁸INER, Ciudad de México, Mexico State, Mexico, ⁹Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan, ¹⁰Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Milano, Italy, ¹¹Center for interstitial and rare lung diseases, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany, ¹²Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia, ¹³Brigham and Women's Hospital, West Roxbury, MA, ¹⁴Department of Dermatology, Stanford University School of Medicine, Stanford, CA, Palo Alto, CA, ¹⁵University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ¹⁶McGill University, Montreal, QC, Canada, ¹⁷Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ¹⁸NIH, Bethesda, MD, ¹⁹University of Bath, Bath, United Kingdom, ²⁰NIH, NIEHS, Chapel Hill, NC, ²¹IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, ²²Karolinska University Hospital and Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, ²³Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²⁴National Institute of Respiratory Diseases, Ismael Cosío Villegas, Mexico City, Mexico, ²⁵University Medical Center Goettingen, Göttingen, Germany, ²⁶University of Milano Bicocca, Milan, Italy, ²⁷Universitat Autònoma of Barcelona, Barcelona, Spain, ²⁸University of Pennsylvania, Wynnewood, PA, ²⁹University of Pavia and Fondazione IRCCS Policlinico San Matteo Hospital of Pavia, Pavia, Pavia, Italy, ³⁰Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: The prevalence of cardiac manifestations has not been comprehensively described in anti-synthetase syndrome (ASSD). In the current study, we report the prevalence of cardiac…
Abstract Number: 0350 • ACR Convergence 2024
Piloting an Adaptation of the Making It Work Program for Systemic Sclerosis: Promising Effects on Job Related Self-efficacy and Risk of Work Disability
Janet Poole¹, Kristine Carandang², Mary Thelander Hill¹, Jessica Salazar¹, Anna Koch³, Timothy Dionne¹ and Diane Lacaille⁴, ¹University of New Mexico, Albuquerque, NM, ²Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA, ³Comfy Couch Counseling LLC, Albuquerque, NM, ⁴Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Although work disability presents a substantial burden for people with systemic sclerosis (SS), there are no tailored programs that aim to support their employment.…
Abstract Number: 0158 • ACR Convergence 2024
Rheumatoid Arthritis Testing Patterns by Physicians and Advanced Practice Providers from a National Commercial Laboratory, 2014 – 2023
Karis Lee¹, Min Kyung Lee², David Alfego³, Kristen Clark⁴ and Stanley Naides⁵, ¹Labcorp, Orlando, FL, ²Labcorp, San Diego, CA, ³Labcorp, Carlsbad, CA, ⁴Labcorp, Raleigh, NC, ⁵Labcorp, Dana Point, CA
Background/Purpose: With the commercialization of new diagnostic and monitoring tests for rheumatoid arthritis (RA) and an increasing number of advanced practice providers (APPs) in the…
Abstract Number: 0298 • ACR Convergence 2024
RAY121, a Novel Recycling Monoclonal Antibody Against Complement C1s: Safety, Pharmacokinetic and Pharmacodynamic Data from a Phase 1a First in Human Clinical Trial in Healthy Adults
Miwa Haranaka¹, Akinori Yamada², Saki Takahashi², Keisuke Gotanda², Sonoko Nakano-Kanatani², Nana Uemura², Kensuke Ohnishi², Masanobu Nishidate², Ichio Ohnami² and Megumi Kai³, ¹Souseikai Hakata Clinic, Fukuoka, Japan, ²Chugai Pharmaceutical Co., Ltd., Tokyo, Japan, ³Oita University, Oita, Japan
Background/Purpose: Complement C1s is one of the major components of the classical complement pathway (CP), and the abnormal activation of CP is implicated in several…
Abstract Number: 0972 • ACR Convergence 2024
Downregulated Fli1 in Scleroderma Myeloid Cells Contributes to Cardiac Fibrosis via a Galectin-3/mTOR Dependent Pathway
Fatima El adili¹, Moyo Mudhibadhi², Giovanni ligresti³, Maria Trojanowska² and Andreea Bujor³, ¹Boston Medical Center, Boston, MA, ²Boston university medical school, Boston, MA, ³Boston University, Boston, MA
Background/Purpose: Cardiac fibrosis is a common complication in Systemic sclerosis (SSc), but the pathogenesis is largely unknown. We have previously shown that monocytes isolated from…
Abstract Number: 1231 • ACR Convergence 2024
Exploring Long-term Complications of Lyme Disease – Insights from a Retrospective Cohort Study
Rafal Ali¹, Yurilu Gonzalez Moret² and Fabian Rodriguez³, ¹Jefferson Einstein Philadelphia, Lansdale, PA, ²Jefferson Einstein Philadelphia, Philadelphia, PA, ³Jefferson Einstein Hospital, Philadelphia, PA
Background/Purpose: Lyme disease is a tick-borne illness with three clinical phases: early localized, early disseminated, and late phase. Other nonspecific symptoms, such as fatigue, body…
Abstract Number: 0343 • ACR Convergence 2024
An Interlaboratory Variability Study of Detection Methods for Myositis-Specific and Myositis-Associated Autoantibodies in Sera from Patients with Idiopathic Inflammatory Myopathies
Georgina Harvey¹, Idil Ashur², Xavier Bossuyt³, Martin Bluethner⁴, Anna Brusch⁵, Chris Bundell⁵, hector Chinoy⁶, Claire Coeshott⁷, Charmaine Donald², Juliet Dunphy⁸, Marvin Fritzler⁹, Adrian Heaps², marie Hudson¹⁰, Masataka Kuwana¹¹, Océane Landon-Cardinal¹², Hui Lu¹, FIONNUALA MCMORROW¹, Marie Mayrhofer⁴, Alain Meyer¹³, Birthe Michiels³, Benoit Nespola¹⁴, Susan O'Loughlin¹⁵, Ivana Putova¹⁶, Johan Rönnelid¹⁷, Ross Sadler¹⁸, Maria Teresa Sanz-Martinez¹⁹, Paul Sciore²⁰, Albert Selva-O’Callaghan²¹, Helena Storfors²², Ernesto Trallero-Araguás²³, Yves Troyanov¹², Jade Tyson², Jiří Vencovský²⁴, Akira Yoshida²⁵ and Sarah Tansley¹, ¹University of Bath, Bath, United Kingdom, ²Severn Pathology, North Bristol NHS Trust, Bristol, United Kingdom, ³University Hospitals Leuven, Leuven, Belgium, ⁴MVZ Labor PD Dr. Volkmann und Kollegen GbR, Karlsruhe, Germany, ⁵Department of Clinical Immunology, PathWest Laboratory Medicine, Perth, Western Australia, Australia, ⁶The University of Manchester, Manchester, United Kingdom, ⁷Advanced Diagnostics Laboratories National Jewish Health, Denver, CO, ⁸Royal United Hospital Bath NHS Foundation Trust, Bath, United Kingdom, ⁹Mitogen Diagnostics Corp, Calgary, AB, Canada, ¹⁰McGill University, Montreal, QC, Canada, ¹¹Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ¹²Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada, ¹³UR3072, Physiology Department, Rheumatology Department, University Hospital of Strasbourg, Strasbourg, France, ¹⁴Laboratoire d’immunologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ¹⁵Greater Manchester Immunology Service, Manchester, England, United Kingdom, ¹⁶Institute of Rheumatology, Prague, Czech Republic, ¹⁷Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, ¹⁸Laboratory of Immunology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, England, United Kingdom, ¹⁹Immunology Division, Vall d'Hebron Hospital, Barcelona, Spain, ²⁰Mitogen Diagnostics Corp., Calgary, ²¹Internal Medicine Department, Universitat Autònoma de Barcelona, Barcelona, Spain, ²²Department of Clinical Immunology and Transfusion Medicine, Uppsala University Hospital, Uppsala, Sweden, ²³Rheumatology Departament, Vall d'Hebron Hospital, Barcelona, Spain, ²⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²⁵Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan
Background/Purpose: In idiopathic inflammatory myopathy (IIM) spectrum diseases, myositis-specific and myositis-associated autoantibodies (MSAs/MAAs) are key markers of disease subtype and prognosis and are considered routine…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].